Phase II study of adjuvant therapy with antiganglioside GD2-specific mouse monoclonal antibody 3F8 [monoclonal antibody 3F8]for metastatic neuroblastoma in second remission
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Monoclonal antibody 3F8 (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 03 Feb 2010 Actual end date (Sep 2001) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2005 New trial record.